Sanofi says profits hit by patent expiry, vaccine problems

October 30, 2013

French pharmaceutical group Sanofi reported a slump in profits for the third quarter of the year on Wednesday owing to the lagging effects of the ending of exclusive patent rights.

The group, downgrading slightly the outlook for full-year results, said that fell, and that an additional factor weighing on performance was production problems for vaccines in the United States.

Net profit for the quarter fell by 21.2 percent to 1.2 billion euros ($1.65 billion) and sales by 6.7 percent to 8.4 billion euros.

Sanofi said that even though it expected to achieve renewed growth in the fourth quarter, the vaccine problem in the third quarter meant that it was lowering its outlook for to the lower end of its previous guidance.

This indicated a fall of about 10.0 percent in net profit.

Managing director Chris Viehbacher said that the effects of losing exclusive rights to some patents had ended in August, and that consequently sales had begun to rise in September.

Related Stories

Sanofi earnings slashed in first quarter

May 2, 2013

(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.

Sanofi warns on '13 profit as Q2 earns slump (Update)

August 1, 2013

Competition from generic drugs continued to hammer French pharmaceutical group Sanofi in the second quarter, the company said Thursday, warning that its full-year earnings could be twice as bad as previous guidance.

Swiss pharma Novartis ups full-year sales outlook (Update)

October 22, 2013

Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...

Recommended for you

Sustaining biomedical research: Med school deans speak out

May 27, 2015

Cuts in federal support and unreliable funding streams are creating a hostile work environment for scientists, jeopardizing the future of research efforts and ultimately clinical medicine, according to leaders of the nation's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.